To: (10)(2e) (10)(2e) (10)(2e) (10)(2e) @minvws.nl]
From: (10)(2e)

Sent: Thur 2/20/2020 12:21:48 AM

Subject: FW: COVID-19: Exchange with Chinese embassy to EU

Van: 10)(2¢ (10)|2e) | Bogin < (10)(2e) @bogin.nl>

Verzonden: woensdag 19 februari 2020 21:07

Aan: (10)(2e) < (10)(2e) @minvws.nl>; (10)(2e) @cbg-meb.nl>; (10)(2e), 0)(2. ((10)(2e), 0)(2. ((1

Van: (10)(2e) 0)(2 (10)(2e) <(10)(2e)@medicinesforeurope.com>

Verzonden: Wednesday, February 19, 2020 10:57 AM Aan: Secretariat < info@medicinesforeurope.com>

Onderwerp: COVID-19: Exchange with Chinese embassy to EU

**Urgentie: Hoog** 

Dear members,

This morning, Medicines for Europe met with the Chinese embassy to the EU regarding the impact of COVID-19 on pharmaceutical production and supplies.

### Resumption of production

China (including through its Ambassador in a press conference) is committed to restarting the production of essential supplies for medicines and recognises that challenge that our industry is facing. The embassy explained that each Chinese province has a production restart plan which depends on the level of viral outbreak. The outlined that some provinces had fully resumed production. We requested more detailed information on the provinces where production has resumed.

### Movement of workers

Similar to the statement above, the embassy explained that the government is considering the lifting of restrictions on internal movement on a province by province basis depending on the level of viral outbreak. The government recognises that this is a major economic and social challenge for China and its customers. Again we requested more detailed analysis in the future.

## Exports/ports

The Chinese embassy confirmed that it was not possible for the virus to be transmitted via trade in goods. Their initial analysis was that shipping trade through ports was not affected by the situation. However, shipping via air freight is affected by travel/airline restrictions. They did not anticipate major problems at shipping ports but agreed to check this issue and keep us informed.

### GMP and other audits

We outlined that companies and regulators would likely be under travel restriction to China because of the viral outbreak. We therefore requested further information on possible locally based auditors that could fulfil these functions on a temporary basis (auditors with knowledge of EU or US regulations like GMP). They agreed to look into this issue.


The meeting was very constructive and open but we could not obtain specific information at this point. We agreed with the embassy to establish a channel of communication to provide our members with as much information as possible on production and shipments to Europe.

We will provide whatever information we can obtain in the future.









#### Disclaimer - E-mail

The information contained in this E-mail is intended for the named recipient(s). It may contain certain privileged and confidential information or information which is otherwise protected from disclosure. If you are not the intended recipient of this message, please immediately send it back to

10)(2e) medicinesforeurope.com and delete it from your computer. You must not copy, distribute or take any action in reference to this information. Because of the nature of the Internet the sender is not in a position to ensure the integrity of this message, therefore the sender disclaims any liability whatsoever in the event of this message having been intercepted and/or altered.

# Disclaimer

The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

This email has been scanned for viruses and malware, and may have been automatically archived by Mimecast Ltd, an innovator in Software as a Service (SaaS) for business. Providing a safer and more useful place for your human generated data. Specializing in; Security, archiving and compliance. To find out more Click Here.